Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

GX Acquisition (GXGX) Competitors

GXGX vs. CHPM, ALUS, SOAC, KALV, RVNC, LRMR, AKBA, TNGX, VERV, and CTNM

Should you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include CHP Merger (CHPM), Alussa Energy Acquisition (ALUS), Sustainable Opportunities Acquisition (SOAC), KalVista Pharmaceuticals (KALV), Revance Therapeutics (RVNC), Larimar Therapeutics (LRMR), Akebia Therapeutics (AKBA), Tango Therapeutics (TNGX), Verve Therapeutics (VERV), and Contineum Therapeutics (CTNM).

GX Acquisition vs.

GX Acquisition (NASDAQ:GXGX) and CHP Merger (NASDAQ:CHPM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment.

61.7% of GX Acquisition shares are owned by institutional investors. Comparatively, 71.7% of CHP Merger shares are owned by institutional investors. 20.0% of CHP Merger shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CHP Merger's return on equity of -245.62% beat GX Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
GX AcquisitionN/A -985.20% -6.02%
CHP Merger N/A -245.62%8.11%

In the previous week, GX Acquisition's average media sentiment score of 0.00 equaled CHP Merger'saverage media sentiment score.

Company Overall Sentiment
GX Acquisition Neutral
CHP Merger Neutral

GX Acquisition received 2 more outperform votes than CHP Merger when rated by MarketBeat users.

CompanyUnderperformOutperform
GX AcquisitionOutperform Votes
2
100.00%
Underperform Votes
No Votes
CHP MergerN/AN/A

GX Acquisition has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, CHP Merger has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GX AcquisitionN/AN/A-$49.26MN/AN/A
CHP MergerN/AN/A$22.22MN/AN/A

Summary

CHP Merger beats GX Acquisition on 5 of the 7 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GXGX vs. The Competition

MetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$102.42M$6.58B$5.15B$8.84B
Dividend YieldN/A8.11%5.06%4.07%
P/E RatioN/A10.97126.3517.61
Price / SalesN/A363.551,230.6086.42
Price / CashN/A52.5940.1936.27
Price / Book20.3610.176.936.36
Net Income-$49.26M$153.36M$119.54M$225.88M

GX Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GXGX
GX Acquisition
N/A$2.85
-3.1%
N/A+1,291.8%$102.42MN/A0.00N/A
CHPM
CHP Merger
N/A$10.18
flat
N/A+0.0%$265.81MN/A0.003
ALUS
Alussa Energy Acquisition
N/A$9.50
flat
N/A+0.0%$341.41MN/A-3.141Gap Up
SOAC
Sustainable Opportunities Acquisition
N/A$10.62
flat
N/A+0.0%$398.25MN/A0.003
KALV
KalVista Pharmaceuticals
3.754 of 5 stars
$9.28
+3.5%
$26.00
+180.3%
+9.1%$400.87MN/A-2.63150Insider Trade
News Coverage
RVNC
Revance Therapeutics
4.0842 of 5 stars
$3.84
+1.1%
$9.66
+151.5%
-49.1%$398.63M$256.95M-1.99597Analyst Forecast
LRMR
Larimar Therapeutics
3.6986 of 5 stars
$6.13
+0.8%
$20.43
+233.3%
+93.6%$391.16MN/A-5.3330Analyst Forecast
AKBA
Akebia Therapeutics
3.9538 of 5 stars
$1.82
+1.7%
$5.75
+215.9%
+75.5%$390.54M$169.88M-7.91167
TNGX
Tango Therapeutics
2.5243 of 5 stars
$3.63
-11.0%
$13.14
+262.1%
-46.4%$389.94M$36.53M-3.1590High Trading Volume
VERV
Verve Therapeutics
2.4495 of 5 stars
$4.60
+1.1%
$25.75
+459.8%
-63.2%$389.44M$11.76M-1.87110
CTNM
Contineum Therapeutics
1.6507 of 5 stars
$14.34
+5.1%
$29.25
+104.0%
N/A$369.69M$50M0.0031

Related Companies and Tools


This page (NASDAQ:GXGX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners